ReviewOsteoarthritis and cartilage open2025
A review of periostin in orthopedics.
Review in Osteoarthritis and cartilage open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunomodulatory cytoskeleton of bionic periosteum affects mitochondrial dynamics to promote osteogenesis.Bioactive materials · 2026Article
- Graphene Oxide-Hydroxyapatite Nanocomposite Coatings and Extracellular Matrix Protein Interactions for Enhanced Osseointegration in Dental Implants.Journal of cellular and molecular medicine · 2026Article
- Periostin as a diagnostic marker and therapeutic target for intervertebral disc degeneration.Journal of orthopaedic surgery and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This review explores periostin (POSTN), a matricellular protein integral to developmental physiological, and pathological processes, by examining its structure, function, and emerging roles in orthopedic and non-musculoskeletal pathologies. It investigates POSTN's potential as a biomarker and therapeutic target in orthopedic diseases, with a focus on post-traumatic osteoarthritis (PTOA), addressing the need for a comprehensive analysis of its current and future clinical significance in orthopedic and musculoskeletal health. Methods: A comprehensive literature review was performed, synthesizing current available literature surrounding POSTN, including findings from human and rodent studies. Data were compiled from multiple large publication databases to provide a broad and current perspective on its roles and applications. Results: POSTN is upregulated in osteoarthritic cartilage and synovial fluid following joint injuries, such as ACL ruptures and anterior shoulder instability events. It promotes cartilage matrix degradation by upregulating catabolic enzymes and inflammatory pathways. Therapeutic silencing of POSTN with siRNA reduces inflammatory mediator expression and mitigates cartilage degeneration in rodent models. POSTN's differential expression across injury stages suggests its potential utility as a biomarker for monitoring disease progression. Conclusions: POSTN is pivotal in musculoskeletal development, fracture healing and bone biology, offering potential as a prognostic biomarker for orthopedic conditions and a tool for monitoring disease progression. Its significant role in PTOA development suggests that targeting POSTN and its downstream inflammatory mediators offer innovative strategies for managing PTOA, warranting further research and clinical exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.